Literature DB >> 3137396

Mass screening for breast cancer: benefits, risks, costs.

J Valentin1, W Leitz.   

Abstract

In general, mass screening for health is of doubtful value, but specific programmes like breast cancer screening could be beneficial. Breast cancer is the major cause of death in middle-aged women in many countries. Experience in Sweden shows that properly designed and performed mammography screening can reduce mortality by one-third, and lead to a better quality of life for treated cancer patients. However, if radiation causes damage proportional to the dose even at low doses, these benefits could be offset by radiogenic cancers in younger age groups (particularly under 40 yr of age). In Sweden, the direct cost of screening equals about 15 pounds sterling. Swedish authorities consider well designed screening justified. Optimization is necessary and involves design, technique, staff competence and organization. An optimized program should save one life in 100 in the screened cohort, while perhaps one life in 10,000 might be lost due to radiogenic cancers (with conventional radiation risk assumptions).

Entities:  

Mesh:

Year:  1988        PMID: 3137396     DOI: 10.1007/bf02985442

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  11 in total

1.  Cancer risk management A review of 132 federal regulatory decisions.

Authors:  C C Travis; S A Richter; E A Crouch; R Wilson; E D Klema
Journal:  Environ Sci Technol       Date:  1987-05-01       Impact factor: 9.028

2.  Comparison of risk estimates using life-table methods.

Authors:  R E Sullivan; P S Weng
Journal:  Health Phys       Date:  1987-08       Impact factor: 1.316

3.  Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981.

Authors:  A L Verbeek; J H Hendriks; R Holland; M Mravunac; F Sturmans; N E Day
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

4.  Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study.

Authors:  H J Collette; N E Day; J J Rombach; F de Waard
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

5.  Cost-benefit analysis in the optimization of radiation protection.

Authors: 
Journal:  Ann ICRP       Date:  1983

6.  Periodic mass screening for breast cancer.

Authors:  S Björnsson
Journal:  Nord Med       Date:  1984

7.  Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses.

Authors:  Y Shimizu; H Kato; W J Schull; D L Preston; S Fujita; D A Pierce
Journal:  Radiat Res       Date:  1989-06       Impact factor: 2.841

8.  Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare.

Authors:  L Tabár; C J Fagerberg; A Gad; L Baldetorp; L H Holmberg; O Gröntoft; U Ljungquist; B Lundström; J C Månson; G Eklund
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

9.  The National Study of Breast Cancer Screening Protocol for a Canadian Randomized Controlled trial of screening for breast cancer in women.

Authors:  A B Miller; G R Howe; C Wall
Journal:  Clin Invest Med       Date:  1981       Impact factor: 0.825

10.  The Edinburgh randomised trial of screening for breast cancer: description of method.

Authors:  M M Roberts; F E Alexander; T J Anderson; A P Forrest; W Hepburn; A Huggins; A E Kirkpatrick; J Lamb; W Lutz; B B Muir
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

View more
  2 in total

1.  Mammography screening: an incremental cost effectiveness analysis of two view versus one view procedures in London.

Authors:  S Bryan; J Brown; R Warren
Journal:  J Epidemiol Community Health       Date:  1995-02       Impact factor: 3.710

2.  Use of hospital services by breast cancer patients by stage of the disease: implications on the costs of cancer control.

Authors:  H Kaija; H Matti; H Tapani
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.